Drug intelligence / Profile preview

Xiere Huazhuo granule

Development stage: Unknown
Lead developer: Shuguang Hospital
Administration: Oral

Overview

Xiere Huazhuo granule is a traditional Chinese medicine (TCM) formulation developed by Professor Ding Xueping at Shuguang Hospital, which is affiliated with the Shanghai University of Traditional Chinese Medicine. The granule is an empirical formula designed to treat obesity by clearing heat (Xiere) and transforming turbidity (Huazhuo), according to TCM principles. It has been evaluated in randomized clinical trials to assess its efficacy and safety compared to Orlistat, focusing on outcomes such as body weight reduction, body fat distribution, blood lipid levels, insulin resistance, and adipokine levels. The formulation aims to address the metabolic underlying causes of obesity through a multi-herbal approach.

Other names: Xiere Huazhuo formula

Beyond the preview

Go deeper on Xiere Huazhuo granule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xiere Huazhuo granule.

Explore the full profile